ITGA6 (Integrin alpha-6) variants and mutations
ITGA6 (also known as Integrin alpha-6) is a human protein-coding gene encoding an integrin alpha-6 protein. It pairs with beta integrin subunits to mediate adhesion to laminins in epithelial basement membranes and other tissues. Biallelic pathogenic variants can cause junctional epidermolysis bullosa with pyloric atresia or related epithelial-adhesion disorders. This analysis covers 1,517 ITGA6 variants and mutations. Of these, 38% have computational variant effect predictions. Disease context includes junctional epidermolysis bullosa with pyloric atresia, Junctional epidermolysis bullosa - pyloric atresia, and epidermolysis bullosa, junctional 6, with pyloric atresia. Example ITGA6 variants include A2T, A2V, and A2S.
Variant analysis overview
- Gene: ITGA6
- Protein: Integrin alpha-6
- UniProt accession: P23229
- Organism: Homo sapiens
- Variants analyzed: 1517
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 1,261 unspecified-consequence records; 4 in-frame deletions; 119 missense variants; 102 synonymous variants; 8 stop-gained variants; 21 frameshift variants; 4 splice-region variants
- Prediction scores: 580 variants have prediction scores (38% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: junctional epidermolysis bullosa with pyloric atresia, Junctional epidermolysis bullosa - pyloric atresia, epidermolysis bullosa, junctional 6, with pyloric atresia, prostate carcinoma, prostate cancer, Varicose veins, alcohol drinking, generalized junctional epidermolysis bullosa non-Herlitz type, junctional epidermolysis bullosa, vein disorder, device complication, benign soft tissue neoplasm.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 14 binding sites; 12 post-translational modification sites.
- Structural context: 24 variants have structural context.
- PTM context: 16 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable ITGA6 variants
Examples include A2T, A2V, A2S, A2G, A2A, A3S, A3T, A3V. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2T (p.Ala2Thr), NCI-TCGA TCGA novel, CADD 25.00, PolyPhen-2 0.64, Variant assessed as somatic; moderate impact.
- A2V (p.Ala2Val), ExAC rs770965047, TOPMed rs770965047, gnomAD rs770965047, CADD 23.20, PolyPhen-2 0.48
- A2S (p.Ala2Ser), gnomAD 2-172427792-G-T, CADD 23.10, PolyPhen-2 0.56
- A2G (p.Ala2Gly), gnomAD 2-172427793-C-G, CADD 23.50, PolyPhen-2 0.64
- A2A (p.Ala2Ala), rs774450070, gnomAD 2-172427794-C-A, CADD 15.50
- A3S (p.Ala3Ser), gnomAD rs1454318766, CADD 22.10, PolyPhen-2 0.14, Uncertain significance
- A3T (p.Ala3Thr), gnomAD rs1454318766, CADD 23.60, PolyPhen-2 0.06, Uncertain significance, Inborn genetic diseases
- A3V (p.Ala3Val), gnomAD 2-172427796-C-T, CADD 19.90, PolyPhen-2 0.00
- A3A (p.Ala3Ala), gnomAD 2-172427797-C-T, CADD 17.50
- A4S (p.Ala4Ser), 1000Genomes rs201418157, ESP rs201418157, ExAC rs201418157, TOPMed rs201418157, Likely benign
- A4T (p.Ala4Thr), rs201418157, ClinGen CA1967693, ClinVar RCV000320725, ClinVar RCV000898687, CADD 19.90, PolyPhen-2 0.01, Likely benign, not provided; Junctional epidermolysis bullosa with pyloric atresia
- A4del (p.Ala4del), gnomAD 2-172427791-GGCC-, CADD 19.40
- A4V (p.Ala4Val), gnomAD 2-172427799-C-T, CADD 21.30, PolyPhen-2 0.00
- A4A (p.Ala4Ala), gnomAD 2-172427800-C-T, CADD 15.60
- G5R (p.Gly5Arg), ExAC rs753245055, TOPMed rs753245055, gnomAD rs753245055, CADD 22.00, PolyPhen-2 0.01
- G5W (p.Gly5Trp), gnomAD 2-172427801-G-T, CADD 24.30, PolyPhen-2 0.94
- G5G (p.Gly5Gly), gnomAD 2-172427803-G-A, CADD 18.40
- Q6H (p.Gln6His), gnomAD rs1371043997, CADD 17.10, PolyPhen-2 0.00
- Q6* (p.Gln6Ter), gnomAD 2-172427804-C-T, CADD 40.00
- Q6R (p.Gln6Arg), gnomAD 2-172427805-A-G, CADD 18.50, PolyPhen-2 0.00
- Q6L (p.Gln6Leu), gnomAD 2-172427805-A-T, CADD 18.40, PolyPhen-2 0.00
- Q6Q (p.Gln6Gln), gnomAD 2-172427806-G-A, CADD 17.80
- L7M (p.Leu7Met), gnomAD 2-172427807-C-A, CADD 23.00, PolyPhen-2 0.58
- L7L (p.Leu7Leu), rs76775089, gnomAD 2-172427807-C-T, CADD 18.10
- L7P (p.Leu7Pro), gnomAD 2-172427808-T-C, CADD 23.20, PolyPhen-2 0.00
- L7Q (p.Leu7Gln), gnomAD 2-172427808-T-A, CADD 24.50, PolyPhen-2 0.49
- C8G (p.Cys8Gly), TOPMed rs1416564292, gnomAD rs1416564292
- C8R (p.Cys8Arg), TOPMed rs1416564292, gnomAD rs1416564292, CADD 23.10, PolyPhen-2 0.01
- C8S (p.Cys8Ser), TOPMed rs1416564292, gnomAD rs1416564292
- C8Y (p.Cys8Tyr), gnomAD 2-172427811-G-A, CADD 22.60, PolyPhen-2 0.00
- C8C (p.Cys8Cys), rs1163393333, gnomAD 2-172427812-C-T, CADD 19.80
- L9S (p.Leu9Ser), gnomAD rs1291296354, CADD 22.90, PolyPhen-2 0.06
- L9L (p.Leu9Leu), rs1339369463, gnomAD 2-172427815-G-A, CADD 21.60
- L10L (p.Leu10Leu), rs373112270, gnomAD 2-172427818-C-A, CADD 17.90
- Y11S (p.Tyr11Ser), gnomAD rs1280984048, CADD 23.20, PolyPhen-2 0.07
- Y11C (p.Tyr11Cys), gnomAD 2-172427820-A-G, CADD 23.10, PolyPhen-2 0.01
- Y11Y (p.Tyr11Tyr), rs756889665, gnomAD 2-172427821-C-T, CADD 20.80
- L12P (p.Leu12Pro), Ensembl rs1574301733
- L12R (p.Leu12Arg), Ensembl rs1574301733, CADD 27.90, PolyPhen-2 0.94
- L12M (p.Leu12Met), gnomAD 2-172427822-C-A, CADD 24.10, PolyPhen-2 0.94
- L12L (p.Leu12Leu), rs778313818, gnomAD 2-172427822-C-T, CADD 20.80
- S13L (p.Ser13Leu), cosmic curated COSV10803, 1000Genomes rs564206622, ExAC rs564206622, TOPMed rs564206622, CADD 17.90, PolyPhen-2 0.03
- A14T (p.Ala14Thr), gnomAD rs1486826628, CADD 20.70, PolyPhen-2 0.06, Uncertain significance, Inborn genetic diseases
- A14V (p.Ala14Val), ExAC rs758278211, gnomAD rs758278211, CADD 19.00, PolyPhen-2 0.00, Uncertain significance, Epidermolysis bullosa, junctional 6, with pyloric atresia
- A14S (p.Ala14Ser), gnomAD 2-172427828-G-T, CADD 19.20, PolyPhen-2 0.01
- A14E (p.Ala14Glu), gnomAD 2-172427829-C-A, CADD 21.10, PolyPhen-2 0.23
- A14A (p.Ala14Ala), rs1683915769, gnomAD 2-172427830-G-A, CADD 14.10
- G15A (p.Gly15Ala), TOPMed rs1257432098, gnomAD rs1257432098, CADD 17.50, PolyPhen-2 0.00, Uncertain significance
- G15E (p.Gly15Glu), TOPMed rs1257432098, gnomAD rs1257432098, CADD 19.50, PolyPhen-2 0.07, Uncertain significance, Epidermolysis bullosa, junctional 6, with pyloric atresia
- G15V (p.Gly15Val), cosmic curated COSV51219
- G15G (p.Gly15Gly), gnomAD 2-172427833-G-A, CADD 18.90
- L16F (p.Leu16Phe), Ensembl rs767272243, CADD 23.80, PolyPhen-2 0.78
- L16H (p.Leu16His), Ensembl rs1683916262
- L16S (p.Leu16Ser), gnomAD 2-172427829-CG-C, CADD 20.00
- L16P (p.Leu16Pro), gnomAD 2-172427835-T-C, CADD 27.80, PolyPhen-2 0.78
- L16L (p.Leu16Leu), gnomAD 2-172427836-C-G, CADD 14.80
- L17P (p.Leu17Pro), gnomAD 2-172427838-T-C, CADD 24.20, PolyPhen-2 0.96
- S18F (p.Ser18Phe), TOPMed rs1683916406, CADD 16.40, PolyPhen-2 0.03
- S18S (p.Ser18Ser), rs1419807933, gnomAD 2-172427842-C-T, CADD 12.60
- R19P (p.Arg19Pro), gnomAD rs1362322499, CADD 21.90, PolyPhen-2 0.00
- R19W (p.Arg19Trp), rs150472149, ClinGen CA1967703, ClinVar RCV002638396, ClinVar RCV002654826, CADD 22.60, PolyPhen-2 0.00, Uncertain significance, not provided; Inborn genetic diseases; Epidermolysis bullosa, junctional 6, with
- R19Q (p.Arg19Gln), gnomAD 2-172427844-G-A, CADD 20.20, PolyPhen-2 0.01
- R19L (p.Arg19Leu), gnomAD 2-172427844-G-T, CADD 21.40, PolyPhen-2 0.00
- R19R (p.Arg19Arg), gnomAD 2-172427845-G-T, CADD 17.30
- L20I (p.Leu20Ile), NCI-TCGA Cosmic COSV9990, cosmic curated COSV99905, CADD 22.60, PolyPhen-2 0.73, Variant assessed as somatic; moderate impact.
- L20F (p.Leu20Phe), gnomAD 2-172427846-C-T, CADD 18.60, PolyPhen-2 0.20
- L20V (p.Leu20Val), gnomAD 2-172427846-C-G, CADD 22.50, PolyPhen-2 0.79
- L20P (p.Leu20Pro), gnomAD 2-172427847-T-C, CADD 23.10, PolyPhen-2 0.97
- L20L (p.Leu20Leu), gnomAD 2-172427848-C-G, CADD 7.25
- G21C (p.Gly21Cys), cosmic curated COSV99905, CADD 17.10, PolyPhen-2 0.00
- G21S (p.Gly21Ser), gnomAD rs1375850035
- G21V (p.Gly21Val), gnomAD rs1436280545, CADD 12.90, PolyPhen-2 0.01
- G21D (p.Gly21Asp), gnomAD 2-172427850-G-A, CADD 13.70, PolyPhen-2 0.05
- G21G (p.Gly21Gly), rs1683917601, gnomAD 2-172427851-C-A, CADD 7.93
- A22G (p.Ala22Gly), TOPMed rs1179548249, gnomAD rs1179548249, CADD 19.20, PolyPhen-2 0.00
- A22T (p.Ala22Thr), gnomAD rs1311063032, CADD 9.43, PolyPhen-2 0.00
- A22S (p.Ala22Ser), gnomAD 2-172427852-G-T, CADD 8.74, PolyPhen-2 0.00
- A22A (p.Ala22Ala), rs376400633, gnomAD 2-172427854-A-G, CADD 17.40
- A23V (p.Ala23Val), Ensembl rs1683918218
- A23T (p.Ala23Thr), gnomAD 2-172427855-G-A, CADD 23.60, PolyPhen-2 0.10
- A23S (p.Ala23Ser), gnomAD 2-172427855-G-T, CADD 23.50, PolyPhen-2 0.44
- A23A (p.Ala23Ala), gnomAD 2-172427857-C-T, CADD 17.90
- F24P (p.Phe24Pro), gnomAD 2-172427831-G-GGG, CADD 24.70
- F24S (p.Phe24Ser), gnomAD 2-172427857-CT-C, CADD 26.70
- F24L (p.Phe24Leu), gnomAD 2-172427858-T-C, CADD 31.00, PolyPhen-2 1.00
- F24I (p.Phe24Ile), gnomAD 2-172427858-T-A, CADD 29.20, PolyPhen-2 1.00
- F24C (p.Phe24Cys), gnomAD 2-172427859-T-G, CADD 31.00, PolyPhen-2 1.00
- F24F (p.Phe24Phe), rs1249910018, gnomAD 2-172427860-C-T, CADD 21.30
- N25D (p.Asn25Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N25H (p.Asn25His), Ensembl rs1574301857
- N25T (p.Asn25Thr), gnomAD 2-172427862-A-C, CADD 27.30, PolyPhen-2 0.93
- N25N (p.Asn25Asn), rs1683918622, gnomAD 2-172427863-C-T, CADD 19.80
- L26V (p.Leu26Val), Ensembl rs954207601
- L26M (p.Leu26Met), gnomAD 2-172427864-T-A, CADD 25.00, PolyPhen-2 1.00
- D27V (p.Asp27Val), gnomAD rs1391510297, CADD 29.40, PolyPhen-2 1.00
- D27T (p.Asp27Thr), gnomAD 2-172427865-TG-T, CADD 25.70
- D27G (p.Asp27Gly), gnomAD 2-172427868-A-G, CADD 31.00, PolyPhen-2 1.00
- T28N (p.Thr28Asn), gnomAD 2-172427871-C-A, CADD 24.40, PolyPhen-2 0.92
- T28T (p.Thr28Thr), gnomAD 2-172427872-T-G, CADD 16.70
- R29L (p.Arg29Leu), cosmic curated COSV99906
- R29Q (p.Arg29Gln), TOPMed rs1460362399, gnomAD rs1460362399, CADD 16.70, PolyPhen-2 0.03
- R29W (p.Arg29Trp), TOPMed rs1683919114, CADD 24.40, PolyPhen-2 0.62, Uncertain significance, Epidermolysis bullosa, junctional 6, with pyloric atresia
- R29R (p.Arg29Arg), rs749534380, gnomAD 2-172427875-G-C, CADD 14.50
- E30* (p.Glu30Ter), rs2468165774, ClinGen CA349291339, ClinVar RCV003723488, Pathogenic
- E30K (p.Glu30Lys), gnomAD 2-172427876-G-A, CADD 22.80, PolyPhen-2 0.17
- E30A (p.Glu30Ala), gnomAD 2-172427877-A-C, CADD 22.60, PolyPhen-2 0.12
- E30E (p.Glu30Glu), rs1006950275, gnomAD 2-172427878-G-A, CADD 19.40
- D31E (p.Asp31Glu), cosmic curated COSV10585, CADD 16.30, PolyPhen-2 0.00
- D31D (p.Asp31Asp), gnomAD 2-172427881-C-T, CADD 16.60
- N32K (p.Asn32Lys), cosmic curated COSV51220, CADD 20.80, PolyPhen-2 0.34
- N32S (p.Asn32Ser), TOPMed rs1020126767, gnomAD rs1020126767, CADD 22.10, PolyPhen-2 0.22, Uncertain significance, Epidermolysis bullosa, junctional 6, with pyloric atresia
- N32N (p.Asn32Asn), rs1683919833, gnomAD 2-172427884-C-T, CADD 16.10
- V33M (p.Val33Met), gnomAD rs965204894, CADD 29.20, PolyPhen-2 0.99, Uncertain significance, Inborn genetic diseases; Epidermolysis bullosa, junctional 6, with pyloric atres
- I34F (p.Ile34Phe), TOPMed rs972560376, gnomAD rs972560376, CADD 26.80, PolyPhen-2 0.80
- I34I (p.Ile34Ile), rs771118805, gnomAD 2-172427890-C-A, CADD 20.50
- R35W (p.Arg35Trp), TOPMed rs1233010383, gnomAD rs1233010383, CADD 28.50, PolyPhen-2 0.69
- R35R (p.Arg35Arg), gnomAD 2-172427891-C-A, CADD 20.80
- R35Q (p.Arg35Gln), gnomAD 2-172427892-G-A, CADD 22.60, PolyPhen-2 0.02
- K36Q (p.Lys36Gln), ExAC rs774309985, gnomAD rs774309985, CADD 27.10, PolyPhen-2 0.72
- K36K (p.Lys36Lys), rs1683920794, gnomAD 2-172427896-A-G, CADD 21.60
- Y37H (p.Tyr37His), ExAC rs746019316, TOPMed rs746019316, gnomAD rs746019316, CADD 15.90, PolyPhen-2 0.00
- Y37D (p.Tyr37Asp), gnomAD 2-172427897-T-G, CADD 15.10, PolyPhen-2 0.00
- Y37C (p.Tyr37Cys), gnomAD 2-172427898-A-G, CADD 16.60, PolyPhen-2 0.04
- Y37Y (p.Tyr37Tyr), rs752456003, gnomAD 2-172427899-T-C, CADD 8.70
- G38R (p.Gly38Arg), gnomAD 2-172427900-G-A, CADD 32.00, PolyPhen-2 1.00
- G38V (p.Gly38Val), gnomAD 2-172427901-G-T, CADD 31.00, PolyPhen-2 1.00
- G38G (p.Gly38Gly), gnomAD 2-172427902-A-T, CADD 18.90
- D39E (p.Asp39Glu), ExAC rs776183303, TOPMed rs776183303, gnomAD rs776183303, CADD 9.46, PolyPhen-2 0.01
- D39N (p.Asp39Asn), gnomAD 2-172427903-G-A, CADD 23.70, PolyPhen-2 0.04
- P40L (p.Pro40Leu), rs761245728, ClinGen CA1967713, ClinVar RCV004405630, ClinVar RCV005023516, CADD 21.70, PolyPhen-2 0.01, Uncertain significance, Epidermolysis bullosa, junctional 6, with pyloric atresia; Inborn genetic diseas
- P40R (p.Pro40Arg), ExAC rs761245728, TOPMed rs761245728, gnomAD rs761245728, CADD 21.90, PolyPhen-2 0.35, Uncertain significance, Inborn genetic diseases; Epidermolysis bullosa, junctional 6, with pyloric atres
- P40P (p.Pro40Pro), gnomAD 2-172427908-C-G, CADD 13.60
- G41R (p.Gly41Arg), gnomAD 2-172427909-G-A, CADD 29.60, PolyPhen-2 0.73
- G41E (p.Gly41Glu), gnomAD 2-172427910-G-A, CADD 23.40, PolyPhen-2 0.05
- S42R (p.Ser42Arg), TOPMed rs1194508063, gnomAD rs1194508063, CADD 24.40, PolyPhen-2 1.00
- S42A (p.Ser42Ala), rs1198032643, gnomAD 2-172427904-AC-A, CADD 16.50
- S42N (p.Ser42Asn), gnomAD 2-172427913-G-A, CADD 27.40, PolyPhen-2 1.00
- S42S (p.Ser42Ser), rs1194508063, gnomAD 2-172427914-C-T, CADD 18.90
- L43I (p.Leu43Ile), ExAC rs777091551, TOPMed rs777091551, gnomAD rs777091551, CADD 25.80, PolyPhen-2 1.00, Uncertain significance, Inborn genetic diseases
- F44L (p.Phe44Leu), gnomAD 2-172427918-T-C, CADD 31.00, PolyPhen-2 1.00
- G45D (p.Gly45Asp), cosmic curated COSV51221
- G45C (p.Gly45Cys), gnomAD 2-172427921-G-T, CADD 32.00, PolyPhen-2 1.00
- G45V (p.Gly45Val), gnomAD 2-172427922-G-T, CADD 29.00, PolyPhen-2 1.00
- G45G (p.Gly45Gly), rs761372308, gnomAD 2-172427923-C-T, CADD 20.70
- S47L (p.Ser47Leu), rs1377038208, ClinGen CA349291454, ClinVar RCV002052423, ClinVar RCV004798938, CADD 28.80, PolyPhen-2 1.00, Pathogenic
- S47S (p.Ser47Ser), gnomAD 2-172427929-G-C, CADD 19.20
- L48M (p.Leu48Met), gnomAD 2-172427930-C-A, CADD 16.80, PolyPhen-2 0.14
- L48P (p.Leu48Pro), gnomAD 2-172427931-T-C, CADD 28.40, PolyPhen-2 0.96
- A49G (p.Ala49Gly), NCI-TCGA Cosmic COSV9990, cosmic curated COSV99906, Variant assessed as somatic; moderate impact.
- A49V (p.Ala49Val), ExAC rs750028773, gnomAD rs750028773, CADD 27.70, PolyPhen-2 0.98
- A49T (p.Ala49Thr), gnomAD 2-172427933-G-A, CADD 25.60, PolyPhen-2 0.83
- M50I (p.Met50Ile), ExAC rs751546962, TOPMed rs751546962, gnomAD rs751546962, CADD 26.80, PolyPhen-2 0.68
- M50L (p.Met50Leu), 1000Genomes rs138572695, ESP rs138572695, ExAC rs138572695, TOPMed rs138572695, Likely benign
- M50T (p.Met50Thr), rs544002743, ClinGen CA1967720, ClinVar RCV002993347, 1000Genomes rs544002743, CADD 26.50, PolyPhen-2 0.93, Uncertain significance, Inborn genetic diseases
- M50V (p.Met50Val), rs138572695, ClinGen CA1967719, cosmic curated COSV10725, ClinVar RCV000885969, CADD 24.70, PolyPhen-2 0.58, Likely benign, not provided; Junctional epidermolysis bullosa with pyloric atresia
- M50K (p.Met50Lys), gnomAD 2-172427937-T-A, CADD 27.80, PolyPhen-2 0.95
- H51N (p.His51Asn), gnomAD rs1372698008, CADD 26.10, PolyPhen-2 1.00
- H51R (p.His51Arg), TOPMed rs1683924104
- H51Y (p.His51Tyr), cosmic curated COSV99905, CADD 26.20, PolyPhen-2 1.00
- H51H (p.His51His), gnomAD 2-172427941-C-T, CADD 21.70
- W52C (p.Trp52Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- W52* (p.Trp52Ter), gnomAD 2-172427943-G-A, CADD 42.00
- W52L (p.Trp52Leu), gnomAD 2-172427943-G-T, CADD 24.80, PolyPhen-2 0.05
- Q53* (p.Gln53Ter), ESP rs374272135, ExAC rs374272135, TOPMed rs374272135, gnomAD rs374272135, CADD 47.00, Uncertain significance
- Q53E (p.Gln53Glu), rs374272135, ClinGen CA1967722, cosmic curated COSV99056, ClinVar RCV003253246, CADD 23.70, PolyPhen-2 0.24, Uncertain significance, Inborn genetic diseases
- Q53H (p.Gln53His), gnomAD 2-172427947-A-C, CADD 23.20, PolyPhen-2 0.13
- L54R (p.Leu54Arg), gnomAD rs1301054995, CADD 29.70, PolyPhen-2 0.91
- L54P (p.Leu54Pro), gnomAD 2-172427949-T-C, CADD 31.00, PolyPhen-2 0.99
- L54L (p.Leu54Leu), rs1683924617, gnomAD 2-172427950-G-A, CADD 17.80
- Q55P (p.Gln55Pro), ExAC rs780969691, gnomAD rs780969691, CADD 23.30, PolyPhen-2 0.13
- Q55del (p.Gln55del), gnomAD 2-172427949-TGCA-, CADD 22.50
- Q55* (p.Gln55Ter), gnomAD 2-172427951-C-T, CADD 42.00
- Q55E (p.Gln55Glu), gnomAD 2-172427951-C-G, CADD 17.70, PolyPhen-2 0.01
- Q55H (p.Gln55His), gnomAD 2-172427953-G-T, CADD 22.20, PolyPhen-2 0.01
- Q55Q (p.Gln55Gln), rs747879718, gnomAD 2-172427953-G-A, CADD 17.00
- P56S (p.Pro56Ser), gnomAD 2-172427954-C-T, CADD 27.20, PolyPhen-2 1.00
- P56P (p.Pro56Pro), gnomAD 2-172427956-C-T, CADD 14.40
- E57D (p.Glu57Asp), TOPMed rs1683925338, CADD 19.20, PolyPhen-2 0.03
- E57K (p.Glu57Lys), TOPMed rs1250054509, gnomAD rs1250054509, CADD 22.70, PolyPhen-2 0.00
- E57G (p.Glu57Gly), gnomAD 2-172427958-A-G, CADD 23.40, PolyPhen-2 0.03
Public ITGA6 analysis runs
- ITGA6 analysis run — ITGA6 (1,517 variants) — completed 2026-08-22